Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study
Published 2021. This article is a U.S. Government work and is in the public domain in the USA..
OBJECTIVES: Using the American College of Cardiology/American Heart Association 2013 atherosclerotic cardiovascular disease (ASCVD) management guidelines, we conducted a retrospective cross-sectional analysis of people living with HIV in the US Military HIV Natural History Study to determine whether individuals were receiving statins when indicated.
METHODS: Prescription data was taken from Military Health System data. Statin eligibility was defined by ASCVD guidelines. We used the 10-year ASCVD pooled cohorts' equation to evaluate risk for each participant.
RESULTS: Across all categories, 31.9% (n = 390) of individuals met criteria for statin use, and when adding these subjects to the number of those already receiving statins (n = 96), 62.1% of all eligible subjects (n = 302/486) were actually receiving statin therapy. In multivariable analysis, individuals of African American race [odds ratio (OR) = 0.48, 95% confidence interval (CI): 0.31-0.73] or Hispanic ethnicity (OR = 0.42, 95% CI: 0.19-0.94) were less likely to receive statin prescriptions than white individuals. Individuals with a higher CD4 count (OR = 1.12, 95% CI: 1.05-1.20 per 100 cells/μL]) were significantly more likely to receive a statin prescription.
CONCLUSIONS: These data highlight discrepancies between ASCVD guidelines and primary care management of people living with HIV (PLWH) in the military health system, along with important racial differences. Targeted interventions are critical to identify and treat appropriate candidates for statin therapy among PLWH in the military and other settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
HIV medicine - 23(2022), 3 vom: 07. März, Seite 249-258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Larson, Derek [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 02.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.13195 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332427250 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332427250 | ||
| 003 | DE-627 | ||
| 005 | 20231225215544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.13195 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332427250 | ||
| 035 | |a (NLM)34704330 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Larson, Derek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 02.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published 2021. This article is a U.S. Government work and is in the public domain in the USA. | ||
| 520 | |a OBJECTIVES: Using the American College of Cardiology/American Heart Association 2013 atherosclerotic cardiovascular disease (ASCVD) management guidelines, we conducted a retrospective cross-sectional analysis of people living with HIV in the US Military HIV Natural History Study to determine whether individuals were receiving statins when indicated | ||
| 520 | |a METHODS: Prescription data was taken from Military Health System data. Statin eligibility was defined by ASCVD guidelines. We used the 10-year ASCVD pooled cohorts' equation to evaluate risk for each participant | ||
| 520 | |a RESULTS: Across all categories, 31.9% (n = 390) of individuals met criteria for statin use, and when adding these subjects to the number of those already receiving statins (n = 96), 62.1% of all eligible subjects (n = 302/486) were actually receiving statin therapy. In multivariable analysis, individuals of African American race [odds ratio (OR) = 0.48, 95% confidence interval (CI): 0.31-0.73] or Hispanic ethnicity (OR = 0.42, 95% CI: 0.19-0.94) were less likely to receive statin prescriptions than white individuals. Individuals with a higher CD4 count (OR = 1.12, 95% CI: 1.05-1.20 per 100 cells/μL]) were significantly more likely to receive a statin prescription | ||
| 520 | |a CONCLUSIONS: These data highlight discrepancies between ASCVD guidelines and primary care management of people living with HIV (PLWH) in the military health system, along with important racial differences. Targeted interventions are critical to identify and treat appropriate candidates for statin therapy among PLWH in the military and other settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a military | |
| 650 | 4 | |a preventative medicine | |
| 650 | 4 | |a primary care | |
| 650 | 4 | |a statin | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Won, Seung Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Ganesan, Anuradha |e verfasserin |4 aut | |
| 700 | 1 | |a Maves, Ryan C |e verfasserin |4 aut | |
| 700 | 1 | |a Kronmann, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Okulicz, Jason F |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Xiuping |e verfasserin |4 aut | |
| 700 | 1 | |a Schofield, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a O'Bryan, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Agan, Brian K |e verfasserin |4 aut | |
| 700 | 1 | |a Deiss, Robert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 23(2022), 3 vom: 07. März, Seite 249-258 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:3 |g day:07 |g month:03 |g pages:249-258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13195 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 3 |b 07 |c 03 |h 249-258 | ||